March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Pfizer (PFE) stock is in focus as a mid-stage trial for the company's investigational breast cancer therapy, atirmociclib succeeds. Read more here.

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration may revoke authorization for Pfizer’s COVID-19 vaccine for healthy children under age 5, the ...

China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more ...

The Trump administration and Pfizer PFE announced an agreement on Sept. 30 that includes most-favored-nation pricing for Pfizer’s drugs in Medicaid programs, discounts for direct sales of Pfizer drugs ...

WASHINGTON (AP) — U.S. regulators approved updated COVID-19 shots Wednesday but limited their use for many Americans — and removed one of the two vaccines available for young children. The new shots ...

Pfizer Inc.'s (NYSE:PFE) COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna ...

By Padmanabhan Ananthan March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin ...

Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...